Clinical trials: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
Metabolic Dysfunction-Associated Steatotic Liver Disease
Efficacy and Safety of Rifaximin-α in Treating MASLD
Study Objective: To evaluate the efficacy and safety of Rifaximin-α in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and investigate the underlying mechanisms by which Rifaximin-α influences…
- Trial name
- NCT07381257
- Testing
- Rifaximin-α (Alfa Wassermann S.p.A., Italy)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Changzheng Hospital
Type 2 Diabetes Mellitus, Metabolic Dysfunction-associated Steatotic Liver Disease
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)
This study aims to explore the efficacy of CMNT, an intermittent energy restriction (iER) intervention, in managing Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease.
- Trial name
- NCT07083336
- Testing
- CMNT diet
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- State Key Laboratory of Subhealth Intervention Technology
Metabolic Dysfunction-Associated Steatotic Liver Disease, Acute Coronary Syndromes (ACS)
MPV as a Predictor for ACS in Patients With MASLD
The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume…
- Trial name
- MPV/ACS MASLD (NCT07487571)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University